News

July 26, 2019

MMRF Launches ‘Immune Atlas’ Aiming for Tailored Myeloma Treatments

News

To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative. Called Immune Atlas, the pilot aims to ... Read more

July 24, 2019

Adding Darzalex to a Velcade-Revlimid Combo Boosts Cancer Disappearance in Newly Diagnosed Multiple Myeloma, Phase 2 Trial Shows

News

Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing complete cancer disappearance, according to top-line results ... Read more

July 22, 2019

Sleep Apnea Drives Multiple Myeloma in Aggressive Way, Mice Study Finds

News

Sleep apnea can drive the development of aggressive multiple myeloma in mice resistant to the cancer, a study found, suggesting that the sleep disorder is a modifiable risk factor for ... Read more

July 19, 2019

Myeloma UK Launches Research Program Focused on Trial Design

News

In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research program. Called the UK Myeloma Research ... Read more

July 17, 2019

Request for Darzalex as Faster and Easier Under-the-skin Infusion for Multiple Myeloma Before FDA

News

Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a faster and easier treatment for people with multiple ... Read more

July 15, 2019

Specific DNA Rearrangement Predicts Treatment Resistance, Poor Outcomes in Multiple Myeloma, Study Suggests

News

A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new study suggests. Testing for ... Read more

July 12, 2019July 15, 2019

FDA Will Review Isatuximab as Potential Therapy for Hard-to-treat Multiple Myeloma

News

The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential therapy for patients with hard-to-treat multiple myeloma, ... Read more

July 10, 2019

FDA Lifts Hold on Phase 3 Trial Testing Venclexta in Myeloma Patients with Common Genetic Abnormality

News

The U.S. Food and Drug Administration (FDA) has lifted its hold on the CANOVA Phase 3 clinical trial, which is evaluating the experimental therapeutic Vencexta (venetoclax) plus dexamethasone in ... Read more

July 8, 2019

FDA Approves Xpovio Combo for Heavily Treated RRMM Patients

News

The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid dexamethasone, for the treatment of adults with relapsed ... Read more

July 3, 2019

Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says

News

Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new therapeutic targets for the disease, ... Read more

Pin It on Pinterest